Teglicar | CAS#250694-07-6 | L-CPT1 inhibitor

MedKoo Cat#: 462052 | Name: Teglicar

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Teglicar, also known as ST1326, is a selective and reversible inhibitor of liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1). Teglicar reduces ketogenesis and glucose production, decreases gluconeogenesis and improves glucose homeostasis.

Chemical Structure

Teglicar

CAS#250694-07-6

Theoretical Analysis

MedKoo Cat#: 462052

Name: Teglicar

CAS#: 250694-07-6

Chemical Formula: C22H45N3O3

Exact Mass: 399.3461

Molecular Weight: 399.62

Elemental Analysis: C, 66.12; H, 11.35; N, 10.52; O, 12.01

Price and Availability

Size	Price	Availability	Quantity
1mg	USD 950.00	2 Weeks
5mg	USD 1,950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1130550-29-6 (cation) 250694-07-6 908566-80-3 (HCl)

Synonym

Teglicar; 4-trimethylammonio-TDCAB; ST1326; ST-1326; ST 1326;

IUPAC/Chemical Name

(R,Z)-N-(1-carboxy-3-(trimethylammonio)propan-2-yl)-N'-tetradecylcarbamimidate

InChi Key

BMZYTDRMCBZVNH-HXUWFJFHSA-N

InChi Code

InChI=1S/C22H45N3O3/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-23-22(28)24-20(18-21(26)27)19-25(2,3)4/h20H,5-19H2,1-4H3,(H2-,23,24,26,27,28)/t20-/m1/s1

SMILES Code

CCCCCCCCCCCCCC/N=C([O-])/N[C@](C[N+](C)(C)C)([H])CC(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 399.62 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Chen W, Wu X, Hu J, Liu X, Guo Z, Wu J, Shao Y, Hao M, Zhang S, Hu W, Wang Y, Zhang M, Zhu M, Wang C, Wu Y, Wang J, Xing D. The translational potential of miR-26 in atherosclerosis and development of agents for its target genes ACC1/2, COL1A1, CPT1A, FBP1, DGAT2, and SMAD7. Cardiovasc Diabetol. 2024 Jan 9;23(1):21. doi: 10.1186/s12933-024-02119-z. PMID: 38195542; PMCID: PMC10777520. 2: Cacciola NA, Sepe F, Fioriniello S, Petillo O, Margarucci S, Scivicco M, Peluso G, Balestrieri A, Bifulco G, Restucci B, Severino L. The Carnitine Palmitoyltransferase 1A Inhibitor Teglicar Shows Promising Antitumour Activity against Canine Mammary Cancer Cells by Inducing Apoptosis. Pharmaceuticals (Basel). 2023 Jul 10;16(7):987. doi: 10.3390/ph16070987. PMID: 37513899; PMCID: PMC10383333. 3: Bertapelle C, Carillo MR, Cacciola NA, Shidlovskii YV, Peluso G, Digilio FA. The Reversible Carnitine Palmitoyltransferase 1 Inhibitor (Teglicar) Ameliorates the Neurodegenerative Phenotype in a Drosophila Huntington's Disease Model by Acting on the Expression of Carnitine-Related Genes. Molecules. 2022 May 13;27(10):3125. doi: 10.3390/molecules27103125. PMID: 35630602; PMCID: PMC9146098. 4: Wunderling K, Leopold C, Jamitzky I, Yaghmour M, Zink F, Kratky D, Thiele C. Hepatic synthesis of triacylglycerols containing medium-chain fatty acids is dominated by diacylglycerol acyltransferase 1 and efficiently inhibited by etomoxir. Mol Metab. 2021 Mar;45:101150. doi: 10.1016/j.molmet.2020.101150. Epub 2020 Dec 23. PMID: 33359403; PMCID: PMC7843514. 5: Skoda J, Borankova K, Jansson PJ, Huang ML, Veselska R, Richardson DR. Pharmacological targeting of mitochondria in cancer stem cells: An ancient organelle at the crossroad of novel anti-cancer therapies. Pharmacol Res. 2019 Jan;139:298-313. doi: 10.1016/j.phrs.2018.11.020. Epub 2018 Nov 16. PMID: 30453033. 6: Singh SB, Kang L, Nawrocki AR, Zhou D, Wu M, Previs S, Miller C, Liu H, Hines CD, Madeira M, Cao J, Herath K, Spears LD, Semenkovich CF, Wang L, Kelley DE, Li C, Guan HP. The Fatty Acid Synthase Inhibitor Platensimycin Improves Insulin Resistance without Inducing Liver Steatosis in Mice and Monkeys. PLoS One. 2016 Oct 3;11(10):e0164133. doi: 10.1371/journal.pone.0164133. Erratum in: PLoS One. 2017 Jan 19;12(1):e0170721. doi: 10.1371/journal.pone.0170721. Spears, Larry D [added]; Semenkovich, Clay F [added]. PMID: 27695056; PMCID: PMC5047649. 7: Conti R, Mannucci E, Pessotto P, Tassoni E, Carminati P, Giannessi F, Arduini A. Selective reversible inhibition of liver carnitine palmitoyl-transferase 1 by teglicar reduces gluconeogenesis and improves glucose homeostasis. Diabetes. 2011 Feb;60(2):644-51. doi: 10.2337/db10-0346. PMID: 21270274; PMCID: PMC3028366.